The FDA is a slow-moving bureaucracy designed to manage risk, not to cure cancer. When news broke that the agency flagged Patrick Soon-Shiong’s ImmunityBio for "misleading" claims regarding their bladder cancer drug, Anktiva, the media followed the standard script: billionaire gets slapped for hubris. They love a narrative where a high-flying tech mogul is humbled by "the science."
They are missing the point. The FDA’s criticism isn’t about medical truth; it’s about a rigid adherence to a communication protocol that is increasingly disconnected from the reality of modern immunotherapy. If you wait for the FDA to approve every adjective in a press release before admitting a drug is a breakthrough, patients die. That is the trade-off no one wants to talk about.
The Compliance Trap
The FDA’s Office of Prescription Drug Promotion (OPDP) operates on a binary: a claim is either backed by a specific, narrow clinical trial endpoint or it is "false and misleading." This creates a sterilized information environment. In the case of Anktiva, the agency took issue with how the company presented efficacy data and compared it to other treatments without "substantial evidence" from head-to-head trials.
Here is the inconvenient reality: head-to-head trials cost hundreds of millions of dollars and take years. By the time a company like ImmunityBio completes a gold-standard comparative study to satisfy a regulatory auditor, the next generation of therapy is already in the pipeline. Soon-Shiong isn't "misleading" the public; he is communicating the relative value of a drug in a market that moves faster than the federal government can process paperwork.
We have built a system where it is legally safer to say nothing than to provide context. When a drug shows a 62% complete response rate in patients who have failed every other therapy, that is a miracle. To the FDA, it’s a "promotional violation" if you don’t mention the specific sub-population constraints in the same font size as the success.
The Myth of the Unbiased Regulator
The "lazy consensus" suggests that the FDA is the objective arbiter of truth. I’ve spent two decades watching these cycles. The FDA is a political entity. It reacts to pressure. When it feels a high-profile figure like Soon-Shiong is getting too much "unearned" sunshine, it flexes.
The agency’s warning letters are often less about protecting patients and more about maintaining its own authority as the sole gatekeeper of medical information. If a billionaire doctor can convince the market that his drug is superior based on real-world data and mechanistic logic before the FDA officially blesses that specific comparison, the agency loses its relevance.
Consider the mechanics of Anktiva. It’s an IL-15 superagonist. It doesn’t just attack a tumor; it trains the immune system’s Natural Killer (NK) cells to recognize and destroy the threat. This is a fundamental shift from the "poison the tumor" philosophy of traditional chemotherapy.
$$E = mc^2$$ is a simple formula, but the biology of immunotherapy is a chaotic system of feedback loops. The FDA’s regulatory framework is still essentially built for small-molecule drugs—pills that do one thing and have one measurable side effect. They are trying to use a map of the 19th-century frontier to navigate the deep ocean of cellular therapy.
Why Comparative Claims Matter
The FDA hates it when companies say their drug is "better" than a competitor without a specific trial proving it. But doctors make these comparisons every single day. If Drug A has a higher response rate in a similar patient population than Drug B, a rational clinician will choose Drug A.
By muzzling companies from making these logical extrapolations, the FDA isn't protecting patients from "misinformation." It is denying them access to the competitive synthesis of data.
I’ve seen companies burn through their entire R&D budget just trying to satisfy the "fair balance" requirements of an ad campaign. That is money that could have gone into the next clinical trial. We are taxing innovation to fund a department of semantics.
The Soon-Shiong Factor: Ego vs. Efficacy
Patrick Soon-Shiong is a polarizing figure. He talks in grand visions of "Cancer Moonshots" and "Healthcare 2.0." The industry hates him because he doesn't play the "shucks, we're just humble scientists" game. He acts like a tech founder.
But here is the counter-intuitive truth: we need the ego. The pharmaceutical industry is filled with "safe" CEOs who manage the decline of their patents and prioritize stock buybacks over risky science. Soon-Shiong puts his own capital on the line to push therapies that the majors wouldn't touch because the regulatory path was too "complex."
When the FDA flags his claims, they aren't flagging a scam. They are flagging a communication style. If Anktiva didn't work, it wouldn't have been approved in the first place. The "misleading" claims are about the degree of its greatness, not its fundamental utility.
The Cost of the "Abundance of Caution"
"Safety first" is a great slogan for a school bus, but it's a death sentence in oncology. Every month the FDA spends bickering with a biotech over the phrasing of a tweet is a month where a patient might not hear about a life-saving option because the company's legal department is too terrified to post it.
We have socialized the risk of "misinformation" while privatizing the burden of terminal illness. If a patient is told a drug is "groundbreaking" and it only extends their life by six months instead of twelve, they haven't been "harmed" by the claim—they've been given a chance they didn't have before. The harm is the silence enforced by the regulatory state.
The FDA’s warning letter to ImmunityBio will be cited by shorts and skeptics as proof of some deep-seated rot. It isn't. It is proof that the innovator is moving faster than the regulator.
If you are a patient with NMIBC (non-muscle invasive bladder cancer), do you care if the company's brochure omitted a secondary endpoint from a trial summary? No. You care that Anktiva is the first major advancement in your treatment in thirty years.
Dismantling the Consensus
The "People Also Ask" sections on search engines will ask: "Is Anktiva safe?" or "Did Soon-Shiong lie?" These are the wrong questions. The right question is: "Why is the system designed to punish companies for being enthusiastic about their success?"
The consensus is that we need more oversight. I argue we need less. We need a "Right to Context."
- Stop treating doctors like children. Physicians can read a clinical study. They don't need the FDA to protect them from a press release.
- Allow real-world evidence to compete with clinical trials. If 5,000 patients in the real world are doing better on Drug A than Drug B, the company should be allowed to say so, even if they didn't run a $500M head-to-head trial.
- Decouple safety from promotion. If a drug is safe and effective enough to be on the market, let the market decide which claims are hyperbolic.
The FDA’s current stance is a relic of a time when there were only three TV channels and people believed everything they read in the newspaper. In the age of decentralized information, the agency’s attempt to control the "narrative" of a drug is not only futile; it’s an obstacle to progress.
Patrick Soon-Shiong isn't the problem. He’s the only one willing to be loud enough to show us how broken the silence has become.
Stop looking at the warning letter. Look at the data the letter is trying to hide behind a veil of "fair balance." The science is real. The "misleading" part is the idea that the FDA is the only one allowed to tell you how much it matters.
Ignore the theater. Focus on the NK cells.
